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Finding new applications for existing pharmaceuticals, known as drug repositioning, is a validated strategy for resolving the 
problem of high expenditure but low productivity in drug discovery. Currently, the prevalent computational methods for drug 
repositioning are focused mainly on the similarity or relevance between known drugs based on their “features”, including chemi-
cal structure, side effects, gene expression profile, and/or chemical-protein interactome. However, such drug-oriented methods 
may constrain the newly predicted functions to the pharmacological functional space of the existing drugs. Clinically, many drugs 
have been found to bind “off-target” (i.e. to receptors other than their primary targets), which can lead to undesirable effects. In 
this study, which integrates known drug target information, we propose a disease-oriented strategy for evaluating the relationship 
between drugs and disease based on their pathway profile. The basic hypothesis of this method is that drugs exerting a therapeutic 
effect may not only directly target the disease-related proteins but also modulate the pathways involved in the pathological pro-
cess. Upon testing eight of the global best-selling drugs in 2010 (each with more than three targets), the FDA (Food and Drug 
Administration, USA)-approved therapeutic function of each was included in the top 10 predicted indications. On average, 60% of 
predicted results made using our method are proved by literature. This approach could be used to complement existing methods 
and may provide a new perspective in drug repositioning and side effect evaluation. 
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Drug discovery is a time-consuming and laborious process. 
To bring a single de novo drug to the market, an average of 
more than $800 million is spent in a time period of ~15 
years [1]. Moreover, about 90% of drugs fail during devel-
opment in phase I clinical trials [2], a rate caused mainly by 
findings of low therapeutic efficacy and/or unacceptable 
toxicity [3,4]. Others are discovered to have similar draw-
backs, even after approval by drug regulatory authorities 
(e.g. the US Federal Drug Administration (FDA)), or post- 
marketing. In exceptional circumstances, it is necessary to 
either modify the drug or even withdraw it from the market. 
The “thalidomide affair”, a highly recognizable example of 
a drug having tragic unintended effects, is a typical example. 
Thalidomide was withdrawn from the market in the early 
1960s because of teratogenic effects. However, it has since 
been reborn as an FDA-approved treatment for cancers and 
lepriasis owing to the discovery of new indications, namely 
immunomodulatory and anti-angiogenic activities [5–8]. 
Despite enormous increases in novel technologies over 
recent times, the productivity of drug discovery efforts has 
actually decreased since the mid-1990s [9]. The need to 
define a novel strategy and/or utilize new resources in drug 
discovery is urgent. Drug repositioning, which aims to dis-
cover new indications for existing drugs, can shorten the 
development cycle and reduce the risk of unacceptable 
pharmacokinetics and safety profiles. Any newly identified 
functions can be quickly evaluated in phase II clinical trials 
[10]. Currently, there are four typical computational meth-
ods in drug repositioning: (i) predicting new drug targets on 
the basis of the chemical structure of the drug together with 
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known information regarding its targets [11]; (ii) identifying 
relationships between drugs based on the similarity of their 
side effects [12]; (iii) analyzing gene expression following 
drug treatment to infer new indications [13]; and (iv) build-
ing a background chemical-protein interactome (CPI) using 
molecular docking and existing data describing drugs and 
adverse reaction proteins [14]. In this final method, the as-
sociation between a queried small molecule and drugs 
within the CPI is used to develop potential indications. All 
of these methods are good predictors of different aspects of 
drug-like activities, and some have been successfully veri-
fied experimentally [11]. However, any newly discovered 
indications are always limited to the diseases of known drug 
therapy, thus it is unsuitable for diseases without any exist-
ing drug therapy. Moreover, these methods give only quali-
tative information regarding the link between drugs and 
disease. 
Drugs usually exert their therapeutic effect by binding to 
a specific protein or nucleic acid [15], the “one disease, one 
drug, one target” paradigm that has dominated the pharma-
ceutical industry for the past few decades. Clinically, how-
ever, many drugs bind “off-target” to proteins other than 
their primary targets, which can lead to unintended effects. 
In the primary disease group, this may lead to undesirable 
side effects but, in another disease group, these off-target 
effects may be beneficial and may thus represent a new in-
dication for the drug [16]. Moreover, from a systems aspect, 
proteins do not always perform their functions in isolation 
but interact with other cellular components to form complexes 
or pathways [17]. Disease, as an intricate phenotype, is usu-
ally related to abnormalities in several pathways [18]. It is 
reasonable to infer that drugs producing therapeutic effects 
may do so not only by targeting the disease-associated pro-
tein(s) directly but also by modulating the pathways in-
volved in the pathological process. With knowledge of drug 
targets and disease-associated proteins accumulating rapidly, 
it becomes possible to investigate the relationships between 
drugs and diseases at the pathway level. In this study, we 
propose a disease-oriented strategy for evaluating the drug- 
disease relationship using pathway profiling. To test this 
method, we took eight multi-target drugs (i.e. having more 
than three known targets) from the top 20 global best-selling 
drugs in 2010 (http://knol.google.com/k/krishan-maggon/top- 
ten-twenty-best-selling-drugs-2010/3fy5eowy8suq3/141#). 
1  Data collection 
1.1  Pathway selection 
A “pathway” is defined as a manually annotated basic bio-
logical functional unit. KEGG [19] serves as a comprehen-
sive resource for pathway information. Considering that 
many basic pathways are involved in pathological disease 
processes, all of the disease pathways in KEGG are excluded. 
As a result, 185 basic pathways were collected, including 
5703 genes. 
1.2  Disease- and disease-associated proteins 
In this work, we integrated two disease- and disease-asso-     
ciated protein databases, using (i) data from a text mining 
exercise to extract the relationship between MeSH items 
and genes [20] and (ii) collection of all disease-protein rela-
tionship pairs indicated as “curated” in the Comparative 
Toxicogenomics Database (CTD) [21]. We found 806 dis-
eases with more than three disease-associated proteins, and 
2616 proteins associated with disease. 
2  Method 
2.1  Pathway profile construction 
In this work, a hypergeom test was taken to evaluate the 
enrichment of disease-associated proteins in each pathway. 
Every disease then obtained a vector with 185 dimensions 
with each element in the vector being a p-value of the hy-
pergeom test. We define the vector as the pathway profile. 
The same approach was used for drug targets. 
2.2  Drug-disease association and significance level 
(i) Calculating drug-disease association.  We assume that a 
drug may have a regulatory effect on a disease if both sig-
nificantly influence the same pathways. Hence, a formula (1) 
was defined to evaluate the association of drug and disease. 
Pathways that contained two or more disease-associated 
proteins and two or more drug targets and that had enriched 
p-values less than 0.01 were identified as being significantly 
affected by both disease and drug, 
 drug,disease drug, disease ,lg .i k i kS p p    (1) 
Here, pdrug, k is the enriched p-value of drug on pathway “k”; 
pdisease i,k is the enriched p-value of disease “i” on pathway 
“k”; k is the pathway which is significantly affected by both 
drug and disease “i”. 
(ii) Random pathway profile construction of drug.  The 
difference in the number of disease-associated proteins may 
lead to bias of the association score, making it necessary to 
evaluate the specificity of associations between drug and 
disease. While retaining the pathway profile sequence of the 
drug, random pathway profiles of the drug were generated 
by randomly sorting the pathway 100000 times. For each 
random profile, the Srandom,disease was calculated according to 
formula (1). 
(iii) Evaluation of association specificity between drug 
and disease.  In this study, the Z-score was used to evalu-
ate the specificity of the association between the drug and 
disease (Z > 2.33), 
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  (2) 
Here, average(Srandom, disease) is the average association score 
between random cases and disease i, std(Srandom, disease) is the 
standard variation of association between random cases and 
disease i. 
3  Results 
Although most drugs are generally designed using the “one 
disease, one drug, one-target” paradigm, drugs with multiple 
targets nevertheless constitute an appreciable proportion of 
known drugs. In the top 20 global best-selling drugs of 2010, 
13 (65%) are multi-target drugs. Among these are eight 
drugs with more than three targets, namely Etanercept, 
Bevacizumab, Aripiprazole, Rituximab, Adalimumab, Quet-
iapine, Trastuzumab and Olanzapine. These drugs were used 
as test samples to predict potential therapeutic functions or 
side effects. According to their advertised pharmacological 
function, these drugs are focused on treating three main 
types of disease: psychosis, rheumatoid arthritis and cancer. 
For each of these disease areas, one drug is discussed in 
detail below. For the other five drugs, see Figures S1–S5. 
3.1  Etanercept 
Etanercept is a protein-based drug used in the treatment of 
autoimmune diseases for its actions as a TNF inhibitor. It is 
co-marketed by Amgen and Pfizer, with the FDA-approved 
therapeutic function of treating rheumatoid arthritis, juve-
nile idiopathic arthritis and ankylosing spondylitis. Besides 
TNF-alpha, etanercept has another 13 targets of unknown 
function described in DrugBank. Table 1 lists the top 10 
diseases associated with Etanercept, as predicted by our 
method. 
Table 1  Top 10 Etanercept-associated diseases based on pathway profile 
MeSH ID Disease Score Z 
D001172a) Arthritis, rheumatoid 36.10333 7.030134 
D008180b) Lupus erythematosus, systemic 35.463 8.174273 
D010518b) Periodontitis 34.2678 8.566442 
D008216 Lymphocytic choriomeningitis 26.62368 6.239536 
D001943b) Breast neoplasms 25.96673 2.991214 
D005909 Glioblastoma 24.95259 3.182368 
D011565b) Psoriasis 24.40725 4.754224 
D010022 Osteopetrosis 23.35165 6.728951 
D000026b) Abortion, habitual 23.2841 6.153638 
D008288 Malaria 22.23864 9.206756 
a) Primary therapeutic function approved by FDA; b) supported by lit-
erature. 
As shown in Table 1, the FDA-approved indication for 
this drug, rheumatoid arthritis, ranked most highly. Another 
five predicted diseases in which Etanercept could be applied 
have been validated by literature. Notably, psoriasis, for 
which Etanercept has undergone clinical phase III trials [22], 
is also included in this top 10. Furthermore, although litera-
ture reporting the use of Etanercept in periodontitis is lim-
ited, this, like rheumatoid arthritis, is a chronic inflamma-
tory disease and shares several risk factors and pathological 
processes [23]. The prevalence of periodontal disease is 
known to increase two-fold among patients with rheumatoid 
arthritis compared to the general population [24], and Di 
Paola et al. [25] found that treatment with Etanercept re-
duces the development of the inflammatory and tissue inju-
ry events associated with periodontitis in a rat model. 
Systemic lupus erythematosus is a systemic autoimmune 
disease that can affect any part of the body. Several studies 
have suggested that Etanercept can induce the pathological 
process of this disease [26–28]. TNF-alpha is also an im-
portant cytokine in the process of breast cancer develop-
ment, and Madhusudan et al. [29] discovered, in phase II 
studies with 16 samples, that Etanercept could attenuate 
breast cancer without major adverse events. 
Elevation of sTNF-R1 and sTNF-R2 is a marker of nor-
mal human pregnancy. In women who suffer habitual abor-
tion, there is no elevation of sTNF-R1 and sTNF-R2 levels 
during pregnancy [30]. Treatment with inhibitors of tumor 
necrosis factor and intravenous immunoglobulin was found 
to improve live birth rates in women with habitual abortion 
[31]. 
No literature evidence was found for direct association 
between Etanercept and lymphocytic choriomeningitis, gli-
oblastoma, osteoporosis or malaria. However, some indirect 
evidence may exist to infer associations. From the pathway 
profiles of Etanercept and lymphocytic choriomeningitis, 
Etanercept may regulate the disease through one or more of: 
the hematopoietic cell lineage; the NOD-like receptor sig-
naling pathway; natural killer cell-mediated cytotoxicity; 
the adipocytokine signaling pathway; and/or osteoclast dif-
ferentiation. For instance, Rodas et al. [32] found that cir-
culating natural killer cell numbers decrease soon after in-
fection of rhesus macaques with lymphocytic choriomenin-
gitis virus. Etanercept is known to reduce the levels of nat-
ural killer cells [33], so may affect lymphocytic choriomen-
ingitis by regulating natural killer cell-mediated cytotoxicity. 
TNF-alpha induces angiogenic factor up-regulation in 
malignant glioma cells [34]. Etanercept may therefore mod-
ulate glioblastoma by inhibiting TNF-alpha. Perturbation of 
the balance between bone formation and resorption can re-
sult in osteopetrosis or osteoporosis [35] and TNF-alpha is a 
known factor in the pathogenesis of various forms of bone 
loss, as supported by both experimental and clinical evi-
dence [36]. Considering the overlap of significantly affected 
pathways, osteoclast differentiation could be a pathway tar-
geted by Etanercept to influence osteopetrosis. 
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Finally, Depinay et al. [37,38] found that treatment with 
TNF-alpha prevents the development of human and rodent 
malarial pre-erythrocytic stages. Therefore, Etanercept may 
increase the risk of malarial infection through its inhibitory 
actions on TNF-alpha. 
3.2  Trastuzumab 
Trastuzumab is an anti-HER2 humanized monoclonal anti-
body that interferes with the HER2/neu receptor, and is ap-
proved for the treatment of ErbB-2-positive metastatic 
breast cancer. DrugBank contains 13 targets of trastuzumab, 
including the primary therapeutic target, ErbB-2. The asso-
ciation score of the pathway profile between trastuzumab 
and diseases was calculated according to the method de-
scribed above. The top 10 predicted associations are listed 
in Table 2. 
Besides breast neoplasms, four other cancers (ovarian, 
head-and-neck and stomach neoplasms, and glioblastoma) 
appear in the top 10. Several studies show that the ErbB 
signaling pathway, which includes the Trastuzumab target, 
ErbB2, is involved in the pathology of these cancers 
[38–41]. In the clinical pharmacological studies, Trastuzumab 
was found to inhibit the growth of tumor cells by affecting 
RhoB and PTEN in an ovarian carcinoma model without 
HER-2 amplification or overexpression [42]. Mineo et al. 
[43] reported the ability of Trastuzumab to induce apoptosis 
and cellular-dependent cytotoxicity in ErbB-2-expressing 
glioblastoma multiforme cell lines. In addition, Trastuzumab 
was shown to enhance the antitumor effect of Gefitinib on 
head and neck squamous cell carcinoma [44]. The ToGA 
trial, an international multicenter phase III clinical study 
involving 24 countries, showed that Trastuzumab is effec-
tive in prolonging survival in HER2-positive carcinoma of 
the stomach [45]. In cytology studies, HER-2 protein is 
overexpressed in 20%–66% of resected non-small cell lung 
cancer, and Trastuzumab was able to inhibit proliferation of 
such cancer cells [46–48]. 
Table 2  Top 10 Trastuzumab-associated diseases based on pathway profile 
MeSH ID Disease Score Z 
D001943a) Breast neoplasms 29.37911 3.454263 
D010051b) Ovarian neoplasms 30.12039 3.567726 
D005909b) Glioblastoma 27.86462 3.634425 
D013274b) Stomach neoplasms 27.64782 4.358746 
D018805 Sepsis 25.68048 3.268015 
D006258b) Head and neck neoplasms 24.57259 3.221091 
D008180 Lupus erythematosus, systemic 23.71224 5.058859 
D008175b) Lung neoplasms 23.51886 2.42144 
D010518 Periodontitis 23.5185 5.506411 
D001172 Arthritis, rheumatoid 20.43737 3.528464 
a) Primary therapeutic function approved by FDA; b) supported by lit-
erature. 
Troponin-I was discovered as prognostic mortality indi-
cator in sepsis patients [49]. However, the expression level 
of troponin-I is elevated after treatment with Trastuzumab 
[50], suggesting a potential risk of sepsis during Trastuzumab 
therapy. 
Rheumatoid arthritis is a chronic inflammatory disease, 
characterised by hyperplasia of synovial tissue and an ab-
normal immune response [51]. ErbB-2 is involved in rheu-
matoid synovial cell growth and Trastuzumab, as an inhibi-
tor of ErbB-2, was able to inhibit this process. Inhibition of 
ErbB-2 may therefore provide a new approach to treating 
rheumatoid arthritis [52]. As with Etanercept, Trastuzumab 
may have a role in the therapy of systemic lupus erythema-
tosus. The Fc-gamma receptor plays an important role in the 
treatment of SLE [53,54] and polymorphisms in this recep-
tor show significant associations with periodontitis [55–57]. 
Because Trastuzumab has been shown to engage in the ac-
tivation/inhibition of Fc-gamma [58], it may be able to 
modulate these two Fc-gamma-related diseases. 
3.3  Aripiprazole 
Aripiprazole is an atypical antipsychotic that acts as a do-
pamine D2 receptor partial agonist. In this study, 25 targets 
collected in DrugBank were used to generate the pathway 
profile. Table 3 lists the top 10 predictions. 
The four diseases most closely associated with Aripipra-
zole are psychiatric disorders, with schizophrenia and bipo-
lar disorder being the two diseases for which Aripiprazole is 
an approved treatment. Although not formally approved, 
Aripiprazole was reported to also have efficacy when ap-
plied in the therapy of autistic spectrum disorders [59–64]. 
In a small sample study, Aripiprazole efficiently reduced 
attention deficit hyperactivity disorder without producing 
any cognitive impairment [65]. 
Obesity, diabetes mellitus and epilepsy were also strongly 
associated side effects predicted by our model. The theory 
Table 3  Top 10 Aripiprazole-associated diseases based on pathway profile 
MeSH ID Disease Score Z 
D012559a) Schizophrenia 30.68264 5.613725 
D001321b) Autistic disorder 27.05887 4.973414 
D001714a) Bipolar disorder 25.20179 6.095611 
D001289b) 
Attention deficit disorder with  
hyperactivity 
23.49487 8.090225 
D002534 Hypoxia, Brain 23.4884 5.244597 
D009765b) Obesity 22.86035 6.226287 
D004829b) Epilepsy, generalized 21.77394 10.16691 
D004409b) Dyskinesia, drug-induced 21.70412 9.777261 
D008881b) Migraine disorders 21.26583 7.631553 
D003921b) Diabetes mellitus, experimental 20.59053 6.530241 
a) Primary therapeutic function approved by FDA; b) supported by lit-
erature. 
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that hypersensitivity of the dopaminergic system may be 
involved in the pathogenesis of migraine has been supported 
by various authors on the basis of clinical, pharmacological 
and recent genetic evidence [66,67], and the D2 partial ago-
nist, Aripiprazole, was found to offer relief from migraine 
headache [68]. Several studies reported that Aripiprazole 
might precipitate dyskinesia and other movement disorders 
[69–71]. Calcium signalling is always altered during hy-
poxia [72], and Aripiprazole is able to modulate calcium 
signaling by regulating the serotonin 5-HT2C receptor [73]. 
This may lead to an association between Aripiprazole and 
hypoxic brain damage. 
4  Conclusion and discussion 
The FDA-approved therapeutic functions of the eight test 
drugs are all included in the top 10 predicted results. Fur-
thermore, 60% of the predictions were supported by clinical 
evidence and/or scientific literature, validating the accuracy 
of our methods. The unidentified functions may represent 
potential new indications for the drug in question. Our 
method is developed based on two biological hypotheses: 
firstly, that proteins always perform their functions within 
pathways, not in isolation; and secondly, that drugs exert 
therapeutic effects by regulating the pathways involved in 
disease pathology rather than directly targeting disease- 
associated proteins. By fully considering the known targets 
of the drug, prediction of pharmacological indications based 
on association between drugs and diseases seems reasonable. 
This unbiased, disease-oriented strategy could be used to 
predict new indications, without the constraint of the exist-
ing pharmacological functional space of the drugs. 
Many pathways contribute to the pathological process of 
disease. Our method comprehensively models the relation-
ships between drugs and diseases, rather than simply the 
primary target pathway, which we hope will lead to the 
discovery of novel therapeutic strategies. For example, dis-
ruption of the immune system is the most frequently used 
approach in the therapy of the autoimmune disorder, rheu-
matoid arthritis. However, Trastuzumab, a monoclonal an-
tibody of ErbB-2, is an effective agent in treating rheuma-
toid arthritis, and does so via a pathway unrelated to immu-
nological modulation. According to the literature, targeting 
growth factors is a promising approach for the treatment of 
rheumatoid arthritis because of the resultant inhibition of 
synovial tissue hyperplasia. 
Multiple targets are necessary in building the pathway 
profile of a drug, rendering it unsuitable for drugs with only 
a single target. Nevertheless, by considering the association 
drugs and disease at the pathway level, it may be possible to 
predict new indications of existing drugs based on gene 
expression data. Disease-oriented and pathway-based ap-
proaches can be used to complement existing methods and 
may provide a new perspective in drug repositioning and 
the evaluation of side effects. 
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